Clinical Trials Browser

urelumab × Lymphoid × Clear all

NCT01471210 2017-04-19

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1 Completed

Lymphoma, B-Cell

NCT01775631 2017-03-31

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Phase 1 Completed

B-Cell Malignancies

NCT02420938 2016-12-06

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell